Last reviewed · How we verify
NCT05992610: iCHRTL
Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy
NA trial testing Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy in Squamous Cell Carcinoma of Oral Cavity in 40 participants. Status unknown.
31 March 2025
Quick facts
| Lead sponsor | Maria Sklodowska-Curie National Research Institute of Oncology |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 40 |
| Start date | 17 February 2022 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy
Conditions studied
- Squamous Cell Carcinoma of Oral Cavity — all drugs for Squamous Cell Carcinoma of Oral Cavity →
- Pharynx Carcinoma — all drugs for Pharynx Carcinoma →
- Larynx Carcinoma — all drugs for Larynx Carcinoma →
- Paranasal Sinus Carcinoma — all drugs for Paranasal Sinus Carcinoma →
Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Who can join
18 and older, any sex, with Squamous Cell Carcinoma of Oral Cavity or Pharynx Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non-commercial clinical study to assess: 1. efficacy of iCHRTL in patients with advanced squamous cell carcinoma of oral cavity, pharynx carcinoma, larynx carcinoma or paranasal sinus carcinoma. 2. tolerability of iCHRTL in patients with advanced squamous cell carcinoma of oral cavity, pharynx carcinoma, larynx carcinoma or paranasal sinus carcinoma. 3. molecular and biochemical effect of low doses of ionizing radiation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05992610
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Squamous Cell Carcinoma of Oral Cavity
Currently open trials in the same condition.
- NCT05144698 — RAPA-201 Therapy of Solid Tumors · Phase 1, PHASE2 · recruiting
Other Maria Sklodowska-Curie National Research Institute of Oncology trials
Trials by the same sponsor.
- NCT07216157 — NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery · NA · recruiting
- NCT06472583 — Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast C · Phase 2 · recruiting
- NCT05271162 — Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines · Phase 3 · recruiting
- NCT06201078 — Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy · Phase 2 · recruiting
- NCT06128863 — Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tiss · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05992610 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maria Sklodowska-Curie National Research Institute of Oncology
- Last refreshed: 15 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05992610.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing